OR WAIT 15 SECS
The recent 26% US tariff on Indian medical device exports poses a critical challenge to India's expanding MedT...
Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, has onboarded Qure.ai, ...
Gurugram-based startup PB Healthcare Services has announced that global investment and transformation company,...
Corning Incorporated has introduced the Corning Low-Flow Reactor System 2 as the latest product line available...
25 Transformative Years of BIOSIMILARS
2025 marks 25 years since India first ventured into the biosimilar space. Over the past quarter century, the country has consistently solidified its position as a global leader in biosimilar approvals, with 135 approvals till January 2025. Initially focused on simpler biologics, the field now includes developing and approving complex monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), a diversified therapeutic focus, and a growing number of innovative players entering the field. As the industry celebrates this silver jubilee, we reflect on the journey that has not only transformed India's biotechnology sector but has also played a pivotal role in making life saving treatments more accessible and affordable worldwide.
For Feedback, please email us at: communications@mmactiv.com
Sign up here to access BioSpectrum India Flip Book.
Sign up here to access BioSpectrum India Flip Book
